Nuix projects solid growth in Annualised Contract Value and revenue for the first half of FY25, despite elongated procurement timelines and increased contract complexity.
Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.
